CSF2 and neoplasm: A bone marrow-targeting nanosystem, CSF@E-Hn, uses haematopoietic stem cell-derived nanovesicles with gripper ligands (aPD-L1, aNKG2D) and colony-stimulating factor (CSF) to activate natural killer cells and target tumour cells.